2023-08-22 10:24:41 ET
More on SELLAS Life Sciences
- SELLAS falls 39% after delaying key milestone for cancer drug
- Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial
- SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study
- Sellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapy
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Earnings data for SELLAS Life Sciences
For further details see:
SELLAS Phase 3 study for AML drug to continue without modifications